Ainos, Inc. (AIMD) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications.
Analysis Summary
Ainos, Inc. reported revenue of $124157 in the most recent fiscal year, growing at a 5-year CAGR of 49.6%.
Trailing-twelve-month margins: gross margin -349.9%, operating margin -1012.1%, net margin -1062.8%.
At the current price of $1.38, AIMD has negative trailing earnings (P/E not meaningful) and an ROE of -217.50%. Market capitalisation stands at $10M.
Balance sheet quality for AIMD: current ratio of 1.1, net debt of $10.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.38 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.82 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -217.50% |
| Return on Invested Capital | -80.51% |
| Return on Assets | -73.89% |
| Gross Margin | -34987.54% |
| Operating Margin | -101210.17% |
| Net Margin | -106283.32% |
Financial Health
| Debt / Equity | 4.21 |
| Current Ratio | 0.13 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AIMD | Ainos, Inc. | $10M | 2.82 | -217.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -1.43% |
| 3 months | -24.59% |
| Year-to-date | -15.85% |
| 1 year | -59.77% |
| 3 years | -91.88% |
| 5 years | -99.39% |
52-Week Range
| 52-week High | $4.44 |
| 52-week Low | $1.26 |
| Avg Volume (90d) | 303K |
Related companies: ADTX · ANL · ATHA · BLRX · DARE · FBLG · GOVX
Explore sector: Healthcare · Biotechnology
More sections of AIMD: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks